alcohol-related%20liver%20disease
ALCOHOL-RELATED LIVER DISEASE

Alcoholic liver disease diagnosis is suggested by an established history of habitual alcohol intake of sufficient length and intensity.
Signs of alcohol abuse and hepatic injury include malnutrition and muscle wasting, cutaneous telangiectasia, palmar erythema, finger clubbing, Dupuytren's contracture, peripheral neuropathy, parotid gland enlargement and signs of gynecomastia and hypogonadism may also be present. Patient may also be asymptomatic.

 

  1. Mathurin P, Mendenhall CL, Carithers RL Jr, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 2002 Apr;36(4):480-487. PMID: 11943418
  2. Arteel G, Marsano L, Mendez C, et al. Advances in alcoholic liver disease. Best Pract Clin Gastroenterol. 2003;17(4):625-647. PMID: 12828959
  3. McCullough AJ, O'Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterolology. Am J Gastroenterol. 1998 Nov;93(11):2022-2036. PMID: 9820369
  4. Jamal MM, Morgan TR. Liver disease in alcohol and hepatitis C. Best Pract Clin Gastroenterol. 2003;17(4):649-662. PMID: 12828960
  5. Stewart SF, Day CP. The management of alcoholic liver disease. J Hepatol. 2003;38(Suppl 1):S2-S13. PMID: 12591182
  6. Maher J. Alcoholic Liver Disease. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger and Fordtran’s gastrointestinal and liver disease: pathophysiology/diagnosis/management. 7th ed. Pennsylvania: Saunders; 2002:1375-1391
  7. MedWormhttp://www.medworm.com/rss/index.php/Gastroenterology/17/http://www.medworm.com/rss/medicalfeeds/specialities/Gastroenterology.xml
  8. Friedman S. Treatment of alcoholic liver disease. UpToDate. http://www.uptodate.com/index. Accessed 19 Sep 2005
  9. European Association for the Study of the Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012 Aug;57(2):399-420. http://www.easl.eu/assets/application/files/5e1b5512fb2cabb_file.pdf. Accessed 20 Feb 2014. PMID: 22633836
  10. O'Shea RS, Dasarathy S, McCullough AJ; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology. 2010 Jan;51(1):307-328. https://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/AlcoholicLiverDisease1-2010.pdf. Accessed 20 Feb 2014. PMID: 20034030
  11. Friedman SL. Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis. UpToDate. http://www.uptodate.com/. 25 Feb 2014.
  12. Singal AK, Bataller R, Ahn J, et al. ACG clinical guideline: alcoholic liver disease. Am J Gastroenterol. 2018 Feb;113(2):175-194. doi: 10.1038/ajg.2017.469. PMID: 29336434
  13. Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-related liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019 Jul 17. doi: 10.1002/hep.30866. Accessed 16 Jan 2020. PMID: 31314133
  14. European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018 Jul;69(1):154-181. doi: 10.1016/j.jhep.2018.03.018. Accessed 16 Jan 2020. PMID: 29628280
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.